Published in
Elsevier, The Lancet, 10142(392), p. 123-133, 2018
DOI: 10.1016/s0140-6736(18)31257-1
Links
Tools
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Journal article published in 2018 by
Kohei Shitara,
Mustafa Özgüroğlu,
M. Bartolomeo,
Yung-Jue Bang,
Maria Di Bartolomeo 
,
Tomasz Olesiński ,
Kei Muro,
Mario Mandalà,
Eray Goekkurt,
Min-Hee Ryu,
Xinqun Chen,
Einat Shacham-Shmueli,
Raymond S. McDermott ,
Lorenzo Fornaro,
Carlos Mayo
and other authors.
,
Tomasz Olesiński ,
Kei Muro,
Mario Mandalà,
Eray Goekkurt,
Min-Hee Ryu,
Xinqun Chen,
Einat Shacham-Shmueli,
Raymond S. McDermott ,
Lorenzo Fornaro,
Carlos Mayo
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.